Atlas Biomed combines DNA and microbiome technologies with digital health data to inspire people into positive lifestyle change and lead them to a healthier future.
Atlas Biomed is a personalised health company, applying the latest genetic technologies to help you navigate towards your potential. To achieve this, Atlas has two tests available in the UK: the Atlas DNA Test and the Atlas Microbiome Test. Both tests feed into the Atlas platform, which allows you to take control of your health through actionable, personalised recommendations.
As co-founder and CEO of the Atlas Biomed Group, Sergey has brought together a deeply experienced team of scientists and bioinformaticians. Under his guidance Atlas has made significant advances in bringing personalised medicine directly to the public. Presently, this team has developed and launched Atlas DNA and Atlas Microbiome tests, that provide actionable, personalized recommendations and allow people to take control of their health.
In Atlas, Artem is implementing modern approaches to management. But the most important thing for him is the development of the company’s products in such a way that they effectively and comfortably help Atlas customers feel better.
Prior to joining Atlas Biomed, Elena was at Richemont for four years, developing and implementing Communications & PR Strategy for a Swiss watch brand IWC Schaffhausen. Before that, she spent over seven years in PR and communication roles within the fast moving and complex commercial environments.
Elena joined Atlas Biomed in December 2018 to increase brand’s visibility and share of voice in major UK media, as well as promote the company and its products oversees and leverage PR opportunities in international markets. She’s leading brand communication strategies for Atlas Biomed across multi-markets, traditional and social media channels and across a variety of stakeholders.
Scientific Advisory Board
Prof. Jim Wilson
He has published over 200 peer-reviewed journal articles, 43 of which were in the top genetics journal Nature Genetics, 10 in Nature and 2 in Science: he is a Thomson-Reuters highly cited researcher, and has an h-index of 65.
Jim initiated two large genetic epidemiology studies in northern Scotland: these platform resources for health research benefit from rich phenotyping, deep genotyping, a tissue biobank and prospective follow up through record linkage and have contributed to the discovery of over 1000 novel associations.
Jim also leads a number of international genetics consortia, regularly contributes to documentaries on genetics and has been involved in the genetic ancestry testing business for over a decade.
Prof. Tatiana Tatarinova
In 2009-2012, Dr. Tatarinova led the Glamorgan Computational Biology Research group at the University of South Wales (United Kingdom). The group was engaged in the plant barcoding efforts, annotation of the oil palm genome, analysis of bacterial evolution, and other projects. In 2013-2017 Tatiana worked at the University of Southern California as an Associate Professor of Research, where her main focus was development of algorithms for provenance prediction. In 2017 Tatiana joined the University of La Verne as Fletcher Jones Endowed Chair in Computational Biology.
Tatiana’s current project include: ancient DNA analysis and paleo-genomics and annotation of plant and animal genomes. Tatiana maintains active collaborations with a number of international research organizations and universities. She organizes international field trips of La Verne students to South East Asia – International Rice Research Institute and Malaysian Palm Oil Board.
Prof. Harold Snieder
He is an expert in design and analysis of genetic and epigenetic epidemiological studies of common complex diseases with a focus on cardiometabolic and renal disease. His group has extensive expertise in quality control, statistical analysis and bioinformatic follow-up of (epi)genome-wide association study (GWAS and EWAS) data.
Harold has published more than 350 articles in peer-reviewed journals. He is a regular reviewer for funding agencies such as NIH and NWO and for journals such as Circulation, Hypertension, Diabetes and Psychosomatic Medicine.
Dr. Vassilis Georgiadis
Previously, Vassilis was one of the founding members of Molecular Warehouse, a UK molecular diagnostics and digital health company, serving as its Director of Operations and Head of Business Development. Following that, he joined the Business & Innovation Group of UCL’s Translational Research Office, where he worked on establishing industrial research collaborations through a faculty-facing role.
Vassilis is a molecular and cell biologist by training, with more than 10 years of academic research in various biomedical areas. Vassilis studied for a BSc in Genetics at Queen Mary University, followed by an MSc in Clinical Neurosciences at UCL and a DPhil in Cell Biology at the University of Sussex.
Dr. Savaş’s education covers medicine (Istanbul Medical School), law (Istanbul Law School), public health (London School of Hygiene and Tropical Medicine), health economics, and health policies (London School of Economics and Political Sciences).
Early in his career, Dr. Savaş served at the Turkish Ministry of Health as Adana Provincial Health Director, World Bank Project Coordinator, and Deputy Undersecretary in charge of health reforms. He joined the World Health Organisation’s European Office in Copenhagen in 1994 as the Regional Advisor for Health Care Policies and Systems. Later he was promoted to the position of European Programme Director, a post he held until his departure from the WHO.
For the past 20 years, Dr. Savaş has pursued the concept of personalised healthcare. His goal is to make these services more predictive, preventive, and comprehensive, as well as precise, evidence-based, and participatory – not only in Turkey but also in Europe and around the globe.
Over the years, Dr. Savaş has been honored with awards and decorations by several European countries for his work in public health.
Prof. Ancha Baranova
Her wet biochemistry lab research is paired with a bioinformatics program. Dr. Baranova is the author of more than 100 research papers and 9 granted US patents.
Dr. Milka Sokolović
Milka has spent 15 years in the academic setting, most at the University of Amsterdam, studying the intermediary metabolism of starvation and obesity. For 7 years she was also teaching subjects like medical biochemistry, DNA technology, metabolism and genomics of disease. Milka has published a number of articles in peer-reviewed journals and has held dozens of presentations at scientific conferences.
In her current role, she oversees EUFIC’s department of Food & Health Science, where the complex scientific topics get translated into “human” language, to help people make sense and use of it. Her responsibilities include setting the annual plan for the Department, guaranteeing the quality and scientific accuracy of the output, manging EUFIC’s Discussion Groups, but also stakeholder engagement, collaboration and influencing, including presenting at high-level events. She is a member of EUFIC’s Exec Team.
Milka also acts as a Director of the Advanced Programme of the ENLP, the European Nutrition Leadership Platform, where food and nutrition professionals get equipped with leadership skills, thereby supported in making a lasting difference in the European public health landscape.
Grigory is the co-founder and CTO of Intento, a Berkeley-based company that builds tools to discover, evaluate and use best-of-breed AI models for enterprise solutions. Before Intento, Grigory was a tech lead of the Yandex News service for more than five years, worked with IBM Watson Research Center as an invited data science expert and had data science/machine learning/deep learning and software engineering roles in other companies.
Grigory has vast teaching experience. He held courses on Digital Signal Processing, Big Data, Data Science, Machine Learning and Deep Learning. Since 2017 he holds a master course on Deep Learning for Biology in HSE.
He was appointed as editor in chief of Clinical Medicine and Commentary (the journals of the Royal College of Physicians), having played a similar role for eight years at Frontline Gastroenterology. He is deeply committed to developing the journals as a valued asset for members of the College.
1989 Completed clinical internship at Wakayama Medical University Hospital
1993 Completed Wakayama Medical University Graduate School (major: Second Surgery), Doctor of Medicine Ph.D
1992-1995 City of Hope National Cancer Institute (Los Angeles), studying abroad
1995 Assistant Professor of Second Surgery, Wakayama Medical University
2000 Lecturer, Institute of Medical Science, University of Tokyo
2005 Associate Professor, Institute of Medical Science, University of Tokyo
2010 OncoTherapy Science Co., Ltd., CEO / President
2015 MerckSerono Co., Ltd., General Manager of MA Oncology
2016 Professor, Showa University Institute of Clinical Pharmacology, Department of Clinical Immunooncology
2018 Chief Professor, Showa University School of Medicine Department of Internal Medicine Department of Oncology/Showa University Hospital Oncology Center Director